Health Risks, Past Usage, and Intention to Use Weight Loss Products in Normal Weight Women with High and Low Body Dysphoria by Whisenhunt, B. L. et al.
Marquette University
e-Publications@Marquette
Marketing Faculty Research and Publications Marketing, Department of
6-1-2003
Health Risks, Past Usage, and Intention to Use
Weight Loss Products in Normal Weight Women
with High and Low Body Dysphoria
B. L. Whisenhunt
Louisiana State University
D. A. Williamson
Louisiana State University
Richard G. Netemeyer
University of Virginia
J. Craig Andrews
Marquette University, craig.andrews@marquette.edu
Published version. Eating and Weight Disorders, Vol. 8, No. 2 ( June 2003): 114-123. Publisher link. ©
2003 Editrice Kurtis. Used with permission.
ORIGINAL 
RESEARCH 
PAPER 
Keywords: 
Body concerns, eating 
disorders, weight loss 
products, advertisements, 
media. 
Correspondence to: 
Donald A. Williamson, M.D., 
Pennington Biomedical 
Research Center, 6400 
Perkins Rd., Baton Rouge, 
LA 70808, USA 
E-mail: WilliaDA@pbrc.edu 
n4 
Vol. 8: 114-123, June 2003 
risks, past 
to use weight loss 
women 
dysphoria 
intention 
normal 
low 
B.L. Whisenhunt*, D.A. Williamson*, R.G. Netemeyer**, C. Andrews*** 
'pennington Biomedical Research Center, Louisiana State University. Baton Rouge, LA, **McIntire School of 
Commerce. Charlottesville, University of Virginia. VA, and ***Marquette University. Milwakee, WI. USA 
ABSTRACT. Objective: There are many health risks involved with the use of weight loss 
products by normal weight women. The mass media may compound this problem through 
the promotion of weight loss products and a thin body size. This study tested women's per-
ceptions of different weight loss product ads to detern1ine if body dysphoria (i.e., an over 
concern with body size and shape in normal weight people) was associated with risk beliefs, 
past behaviors, and intention toward using weight loss products. Method: Normal weight 
women (age range = 18-41 yr), who were classified as either high (n=45) or low (n=43) on a 
measure of body dysphoria, rated different weight loss products according to their percep-
tion of health risks, past behavior, and their intention to consume the products. These prod-
ucts were a dietary fat substitute (olestraJ a prescription obesity medication (sibutramine), 
and an over-the-counter appetite suppressant (phenylpropanolamine). Results: High body 
dysphoric women reported higher intentions to use the products as well as increased prior 
use of two of the three weight loss products. High body dysphoric women did not believe 
that these weight loss products were harmless. They recognized potential health risks associ-
ated with using such products, but nonetheless, expressed intention to use these weight loss 
products at a higher frequency. Also, several variables related to body image were found to 
effectively discriminate normal weight women at risk for abusing weight loss products. 
Discussion: This study found that women who do not need to lose weight but have signifi-
cant body image concerns were willing to use potentially harmful weight loss products 
despite the knowledge that such products might pose significant health risks. Techniques uti-
lized by advertising regulatory agencies such as warning labels did not have a strong deter-
rent effect for stated intentions to use the products. Implications of these findings for public 
health policy issues were discussed. 
(Eating Weight Disord. 8: 114-123,2003). ©2003, Editrice Kurtis 
INTRODUCTION 
Problems related to being overweight are 
estimated to account for 70 billion dollars 
annually in the United Statesin health-relat-
ed costs (1). In addition, 33 billion dollars 
are spent per year on diet pills, exercise 
programs, and appetite suppressants, mak-
ing dieting the norm rather than the excep-
tion (2). A recent report of a mUlti-agency 
conference on weight loss products and 
programs sponsored by the Federal Trade 
Commission (FTC), American Society for 
Clinical Nutrition, National Institute of 
Diabetes, and the Center for Disease 
Control and Prevention estimates that 40% 
of women in the U.S. are currently trying to 
lose weight (1). The primary reason for try-
ing to lose weight is "a concern for physical 
appearance," and many of those attempting 
to lose weight are not overweight (based on 
height/weight ratios), i.e., normal weight 
women (1). 
Ads promoting the use of weight loss 
products typically aim to promote a healthi-
er lifestyle. However, these same ads may 
be interpreted in ways that are unhealthy 
by a minority of people who are "at risk" 
for psychological/physical problems (e.g., 
women with eating disorders). Several 
studies suggest that a motivating factor for 
unhealthy weight reduction behaviors may 
be media pressure in the form of weight 
loss ads. For example, Burton et a1. (3) and 
Whisenhunt et al. (4) found a significant rela-
tionship between images in weight loss ads and 
unhealthy dieting behaviors. Rabak-Wagner et 
al. (5) reported that a primary factor affecting 
unhealthy dieting in college-aged women is the 
information in ads for weight loss products. 
Grigg et al. (6) found that over half of the ado-
lescent girls they sampled had used at least one 
unhealthy weight reduction method and 36% 
admitted to extreme weight loss methods 
including crash dieting, fasting, diet pills, and 
diuretic use under the assumption that these 
methods were harmless. In sum, normal weight 
women may choose to use weight loss products 
for aesthetic purposes under the misperception 
that such products are without health risk. 
Women ,,\lith body image disturbances may 
be at risk for abusing commercial weight loss 
products and may misinterpret the advertise-
ments for these products. Research on cogni-
tive biases has found that people diagnosed 
with an eating disorder tend to notice and 
recall information related to food and body 
shape. Research on cognitive biases has also 
shown that normal weight women who are 
overly concerned with body size and shape 
(called body dysphoria) have information pro-
cessing biases similar to women who meet the 
diagnostic criteria for an eating disorder (7). 
Cognitive biases are most prominent when 
ambiguous stimuli related to fatness, dieting, 
and control of food intake are presented. In a 
recent review, Williamson (8) reports that 
advertisements for weight loss products have 
many of the ambiguous features of the stimuli 
used in studies examining cognitive bias in 
body dysphoria. 
Marketing research has suggested that con-
sumers often misinterpret or misuse information 
presented in ads, particularly if the ad is ambigu-
0us or does not include a disclosure (9, 10). For 
example, Burke et al. (11) found that consumers 
may misinterpret information presented in 
advertisements, but presenting truthful informa-
tion/disclosures can serve to reduce such misin-
terpretations. Andrews et al. (9) examined how 
consumers interpret nutrient content claims 
made in advertisements. They found that the dis-
closures (in general) were successful in reducing 
favorable evaluations of disease-risk and nutrient 
content generalizations as compared to the no 
disclosure control group. 
The current study tested how an "at risk" pop-
ulation (Le., normal weight women with high 
body dysphoria) processes information in weight 
Weight loss products and nornlal weight women 
loss ads. The current study had two objectives: 1) 
to investigate the potential effects of advertise-
ments for weight loss products in normal weight 
women high or low in body dysphoria, and 2) to 
identify body image variables that may put nor-
mal weight women at risk for abusing weight 
loss products, and that discriminate between 
high and low body dysphoric groups. 
METHOD 
Weight loss products studied 
Three different classes of weight loss prod-
ucts were included in the study: a prescription 
obesity medication, a dietary fat substitute, and 
an over-the-counter appetite suppressant. 
Sibutramine (the prescription drug selected for 
use in this study)' is an appetite suppressant 
that works by inhibiting reuptake of norepi-
nephrine, serotonin, and dopamine (12). 
Sibutramine can only be obtained through a 
physician's prescription, and it is only intended 
for use in people who have obesity which caus-
es significant health problems that are greater 
than the potential side effects of the medication 
(increased heart rate and blood pressure). 
olestra (the dietary fat substitute selected for 
use in this study) is a fat substitute that gives 
food the same texture as fat but is not absorbed 
from the intestine and does not contribute to 
calories (3). One concern with this product is 
that some people may believe that olestra has a 
laxative effect, making it susceptible to abuse 
by persons with eating disturbances (14). The 
over-the-counter appetite suppressant selected 
for use in this study contains phenyl-
propanolamine (PPA), a sympathomimetic 
amine used to curb the appetite (15). 1 Each of 
the three weight loss products contains a label 
on the package describing possible side effects. 
Participants 
A total of 626 females enrolled at a major uni-
versity were screened for inclusion in the study 
sample. To be included in the study, participants 
were required to 1) have high or low body dys-
phoria as defined by their score on the Body 
Shape Questionnaire (BSQ) (16), 2) be in the nor-
mal body weight range, as defined by a body 
mass index (BMI=kg/m2) between 20 and 25, and 
3) be older than 18 years of age. Participants con-
sidered high in body dysphoria obtained a score 
in the upper quartile on the BSQ, while partici-
pants considered low in body dysphoria obtained 
lFollowing data collection in this study, phenylpropanolamine was taken off the market by the Food and Drug 
Administration due to concerns about health risks associated with the use of this medication. 
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a score in the lower quartile on the BSQ. Based 
on data from Muller et al. (17), cut-off scores on 
the BSQ for the upper and lower quartiles were 
established (upper quartile ;:::118; lower quartile 
~67; M=93.99, SD=35.02). 
Of the 626 initially screened, 105 women (age 
range == (8-41) participated in the second phase of 
the study based on their classification as either 
high or low body dysphoric and their self-report-
ed normal weight. Participants were tested 1 day 
to 1 week after the initial screening. The BSQ 
was re-administered at the time of testing to 
ensure that the test scores remained in the upper 
or lower quartiles. Participants who obtained 
BSQ scores within 5 points of the original cut-off 
scores were included in the study (resulting in 
new cut-off scores of 113 and 72 for high and 
low body dysphoria respectively). Those who 
scored greater than 5 points above or below the 
cut-off score on the second administration of the 
BSQ were excluded from the study. Participants 
who had an eating disorder as defined by DSM-
IV or were not of normal weight were excluded 
from the study. In the second phase of the study, 
17 of the 105 participants were excluded from 
the study because: a) BSQ scores were 5 points 
above or below the cut-off (n=2); b) BMI was 
below 20 or greater than 25 (n=12); or c) the 
presence of an eating disorder (n=3). The final 
sample consisted of 88 women, 45 with high 
body dysphoria and 43 with low body dysphoria. 
The mean weight of participants was 130 pounds 
(SD=12.0 Ibs), and mean height was 64 inches 
(SD=2.3 inches). The mean age of participants 
did not differ across the high (M=19.4, SD=2.0) 
and low (M=20.6, SD=4.0) body dysphoria 
groups. This sample of women included a 
diverse mixture of racial and ethnic groups: 76% 
Caucasian, 13% African American, 6% Asian, 
2.5% Hispanic, and 2.5% Native American. 
Procedure 
In the first phase of the study, participants 
were screened using the BSQ and self-reported 
height and weight. Participants who met the 
primary inclusion criteria for the study were 
asked to return. In the second phase of the 
study, participants were told that the experi-
ment was designed to assess consumer's atti-
tudes about various products based on viewing 
advertisements for those products. After view-
ing the ads, participants responded to the 
dependent measures and a memory quiz includ-
ed to test the participants' comprehension of 
the information presented in the ads. Next, par-
ticipants completed a questionnaire packet con-
taining all other measures, were weighed and 
measured, and screened for eating disorder 
symptoms. 
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Measures: Classification/screening 
variables 
Body Shape Questionnaire (BSO) 
To examine our first study objective, a mea-
sure of body dysphoria was needed to classify 
subjects as high or low in body dysphoria. As 
previously stated, the BSQ was used. The BSQ is 
a 34-item self-report questionnaire used to 
assess concerns about body shape and size 
where all items are scored on 6-point Likert 
scales ranging from "never" to "always." The 
term body dysphoria was coined by Williamson 
et al. (18) to describe normal weight people who 
are preoccupied \'Vith body size and shape (but 
not other body concerns). Williamson hypothe-
sized that this group of nonclinical subjects 
would have many of the characteristics of peo-
ple diagnosed v\rith eating disorders. In subse-
quent studies, the BSQ has proven to be useful 
in defining nonclinical subjects of normal weight 
status with weight concerns similar to eating 
disordered patients (19). 
Interview for the diagnosis of eating disor-
ders - Fourth revision fIDED-IV) 
The IDED-IV is a semi-structured clinical 
interview found to be a valid and reliable 
assessment instrument for diagnosing anorexia 
nervosa, bulimia nervosa, binge eating disor-
der, and eating disorder not otherwise speci-
fied based on DSM-IV criteria (20). The IDED-
IV was administered to participants as a 
screening tool for the presence of an eating 
disorder. Three participants were excluded 
from participation based upon this screening 
interview. 
Measures: Independent/discriminator 
variables 
To examine our second objective, several 
body-image related independent variables 
were measured and used for discriminant 
analyses. All of these measures were respond-
ed to in the second phase of the study, after the 
experiment was conducted. These measures 
are as follows: 
Three-Factor Eating Questionnaire (TFEQ) 
Restrictive eating attitudes were measured 
with the three scales of the TFEQ: 1) dietary 
restraint, 2) disinhibition, and 3) perceived 
hunger. All three scales have been reported to 
have good test-retest reliability (21). The 
TFEQ was used to examine whether differing 
levels of eating restraint are associated with 
high ratings of intent to use weight loss prod-
ucts, and if the TFEQ scales were effective 
discriminators of high and low body dysphor-
ic groups. 
-- .... ~ ...... ~ ........ -- ......•. -."~~~~--............. ------'----
Produd 
Psychosocial Risk Factors Questionnaire 
(PRFQ) 
The PRFQ is an 1S-item self-report measure 
containing four sub-scales: 1) concern for phys-
ical appearance, 2) media pressure for thinness, 
3) social pressure for thinness, and 4) percep-
tion of physical appearance. The PRFQ has 
demonstrated adequate concurrent validity and 
test-retest reliability for each of the four sub-
scales (4). The PRFQ scales are used to examine 
whether its sub-scales are associated with high 
ratings of intent to use weight loss products, 
and if they were effective discriminators of 
high and low body dysphoric groups. 
Beck Depression Inventory - Second edition 
(EDI-II) 
The BDHI is a 21-item self-report measure 
designed to assess severity of depressive symp-
toms (22). The BDI-II was used to determine if it 
was associated with high ratings of intent to 
use weight loss products, and if it was an effec-
tive discriminator of high and low body dys-
phoric groups. 
Measures: Dependent variables 
Past Product Use 
Past usage of diet products was assessed via 
the following question for each of the three 
products: Have you ever used the product or 
one similar to it? (yes/no). 
Intention and risk 
For each product, participants completed 
seven items adapted from Andrews et al. (9, 
23) assessing behavioral intention to use the 
product in the future and the perceived risk 
TABLE 1 
Disclosures for the three weight loss products. 
Control version Enhancement 
Disclosure version version 
When calling PPAcan 
10 place makeweight 
PPA PPApilis 
may cause 
hypertension, 
seizures, or 
psychotic reactions. 
Olesko This product may 
cause abdominal 
cramping, nausea, 
or diarrhea. 
Sibutramine Sibutramine may 
cause high 
blood pressure, 
insomnia 
or conslipation. 
your order, 
mention this 
advertisement. 
Look for 
money-saving 
coupons in 
your local 
newspaper. 
For more 
information 
about sibutramine, 
please contact 
your physician. 
loss OOS~i 
affordabe, 
and fast. 
Eat oieslra 
to lose weight 
and still 
eat great. 
Use sibutramine 
to shed those 
extra pounds 
within weeks. 
Weight loss products and normal weight women 
associated with the product. This division was 
based on theoretical grounds as well as 
empirical evidence. The two questions com-
prising the behavioral intention scale ("How 
likely would you be to use this product in the 
future?" and "How often would you consider 
using this product?") were highly correlated 
(r =0.71, p<0.001) but were not highly corre-
lated with the other three items. The remain-
ing three questions comprised the perceived 
risk scale ("Do you consider this product to 
be healthy/unhealthy for you?" " Do you 
agree/disagree that regular use of this prod-
uct would contribute to the risk of health 
problems?" and "Do you believe that the ben-
efits gained from using this product regularly 
would outweigh the risks involved?") and 
were also positively correlated with r-values 
ranging from 0.33 to 0.55) (Coefficient alpha = 
0.67). Each question could be rated from O. to 
4. Therefore, by adding the ratings, the range 
of possible scores for the behavioral intention 
scale was 0 to 8, and the range of possible 
scores for the perceived risk scale was 0 to 12. 
Advertising stimuli 
The advertising stimuli consisted of three 
experimental ads of weight loss products and six 
dummy ads. The six dummy ads were included 
as test stimuli in order to disguise the purpose of 
the study and included the following products: 
1) over-the-counter headache medication con-
taining acetaminophines, aspirin and caffeine, 
2) prescription contraceptive, medroxyproges-
terone, 3) tampons, 4) prescription allergy med-
ication, fexofenadine hydrochloride, 5) hair dye 
and 6) whitening toothpaste. Original advertise-
ments in published journals or magazines were 
used. As previously stated, the experimental 
products were olestra, sibutramine, and PP A. 
Each product had three versions (nine ads total): 
one containing additional information about the 
health risks associated with the product (deter-
rence version), one containing additional infor-
mation unrelated to the product's function (con-
trol version), and one containing additional 
information intended to enhance perceptions of 
the product's efficacy (enhancement version). 
The information added to each of the weight loss 
ads according to disclosure version is shown in 
Table 1. All of the ads were in full color. For each 
version of all nine ads (three experimental and 
six dummy ads), additional information was 
added at the bottom of the ad in a white box, 
keeping font size and number of additional 
words (nine words) constant across all ads. 
Within the· entire study, each ad had trll'ee ver-
sions of product disclosure statements, but any 
one participant viewed only one version of each 
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ad with the same type of product disclosure 
statement (deterrent, control, or enhancement) 
for all of the weight loss ads. 
Prior to initiation of the study, n,y-o steps were 
taken in order to establish the content validity of 
the advertising stimuli. First, n-vo expert judges, 
each with over 15 years of research experience 
in marketing and advertising research, rated the 
advertisements. The raters were asked to exam-
ine each of the three versions of the weight loss 
product advertisements and rate them according 
to several dimensions. Expert ratings indicated 
high levels of authenticity, salience, and consis-
tency with actual advertising formats (mean rat-
ings ranging from 5.0 to 6.3 on a 7 -point Likert 
type scale). The second step taken to ensure the 
content validity of the ad stimuli was a pilot test 
of the advertisements with college student par-
ticipants. Participants included 30 undergraduate 
females who viewed all nine advertisements. 
After viewing each of the nine ads, participants 
completed the dependent variable measures and 
a four-item memory quiz concerning the content 
of the advertisements. The quizzes were included 
as a manipulation check to determine how well 
participants attended to the information present-
ed in the ads as well as to test the possibility of 
fatigue effects. Participants were later asked 
open-ended questions about what they thought 
the study was about, whether or not they 
believed that there was extra information added 
to the ads, whether or not they noticed anything 
strange about the ads, or if they thought the ads 
appeared realistic. There was no order effect for 
the quiz scores indicating the absence of a 
fatigue effect, and none of the pmiicipants accu-
rately guessed the purpose of the study. 
RESULTS 
Objective one: Comparisons for past 
product usage, intention, and risk 
We hypothesized that women with high levels 
of body dysphoria would report higher past 
usage of the weight loss products than would 
women with low levels of body dysphoria. Table 
2 summarizes percentages of positive and nega-
tive responses across the three different prod-
ucts as a function of level of body dysphoria. A 
2X2 chi-square contingency table indicated that 
responses to the question "Have you ever used 
the product or one similar to it?" differed signif-
icantly as a function of body dysphoria for PPA 
[X2 (1) = 15.10, p<0.0001] and sibutramine [X2 (1) 
= 4.74, p<O.05]. That is, for PPA and sibu-
2The data pertaining to the 6 dummy ads were not analyzed. 
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TABLE :2 
Prior knowledge use of the experimental weight los5 products. 
"Hal/eyall 
el/er heard 
of !his 
before?fl 
aD yes 110 X2 yes 110 
PPA L 2.3% 97.9% 9.3% 90.7% 
0.30 
H 4.4% 95.6% 46.7% 53.3% 
Olestra 97.7% 2.3% 76.7% 23.3% 
0.001 
H 97.8% 2.2% 91.1% 8.9% 
Sibutramine L 48.8% 5l.2% 4.7% 95.3% 
0.04 
H 46.7% 53.3% 20.0% 80.0% 
Note: BD = body dysphoria group; L =Iow; H =high, 
·p<O.lO, '*p<O.05, ***p<O.Ol 
tramine, participants with high levels of body 
dysphoria reported increased prior use of the 
product (or a similar product) as compared to 
participants with low levels of body dysphoria. 
There was only a marginally significant result 
for olestra [X2 (1) = 3.40, p<0.10]. (As a data 
check, responses to the question "Have you 
ever heard of this product before?" did not dif-
fer across high and low body dysphoric groups 
for any of the three weight loss products) (Table 
2). Thus, the hypotheses that past usage would 
be higher for the high dysphoric group was 
supported for n-vo products, and was marginal-
ly supported for the third. 
We also hypothesized that women with high 
levels of body dysphoria would report a higher 
intent to purchase and a lower perceived risk for 
the weight loss products than would women 
with low levels of body dysphoria. Multivariate 
Analysis of variance (MAN OVA) was used to 
evaluate group differences in ratings on inten-
tion and risk. A 2 (level of body dysphoria) x 3 
Cad version) x 3 (product type) repeated mea-
sures MANOV A was used. The MANOV A was 
performed with two between subjects factors 
(level of body dysphoria and ad version) and one 
vvithin subjects factor (product type).2 Significant 
main effects were obtained for level of body dys-
phoria [F (2, 81) = 19.80, p<O.OOO1], product type 
[F (4, 79) = 67.61, p<0.0001], and ad version [F (4, 
164) = 2.43, p=0.05]. There were no significant 
interactions between body dysphoria, ad ver-
sion, or product type. 
X2 
15.1**' 
3.4* 
4.7** 
weight loss products and normal weight women 
TABIf 3 
Means and standard deviations on intentions scale and perceived risks scale for the three weight loss products. 
Product ail'itudes 
Product questionllaire scale level of body dysphoria Moon SO 
PPA Behavioral intentions Low 
High 
Perceived risks low 
High 
Olestra Behavioral intentions low 
High 
Perceived risks Low 
High 
Sibulramine Behavioral intentions low 
High 
Perceived risks low 
High 
Analyses of variance (ANOVA) for each 
dependent variable were conducted as follow-
up tests to the MANOV A. The ANOVA for 
main effect of level of body dysphoria was sig-
nificant for the behavioral intention scale [F (1, 
82) = 32.31, p<O.OOO1], but not for the perceived 
risk scale [F (1,82) = 3.13, p>O.051. High body 
dysphoria was associated with higher intent to 
use PPA [F (1, 82) = 17.75, p<O.OOO1], olestra [F 
(1, 82) = 12.84, p<O.05], and sibutramine [F (1, 
82) = 27.71, p<O.0001]. There was no main effect 
of body dysphoria for perceived risk associated 
with PPA [F (1,82) = 1.86, pO.05], olestra [(F (1, 
82)=0.51, p>0.05], or sibutramine [F (1,82) = 
2.18, p>0.05]. Table 3 summarizes the means 
and standard deviations for each of the three 
products on the behavioral intention scale and 
perceived risk scale. 
A second hypothesis was that a "deterrent 
disclosure" (Le., negative health side effects) 
would result in the lowest behavioral intention 
score and highest risk score in comparison to a 
"control" (neutral information) or "enhance-
ment disclosure" (Le., positive weight-loss 
effects of the product). The only significant 
effect for ad version was found for olestra 
[F (2,82) = 4.48, p<0.05]. Tukey's HSD post hoc 
analyses were conducted for the main effect of 
ad version on the olestra intention scale to 
determine which ad condition affected olestra 
behavioral intention scores most strongly. The 
olestra intention score for the deterrence dis-
closure (M=3.23, SD=2.18) was significantly 
lower than the control CM=4.34, SD=1.59) and 
0.53 1.16 
2.18 2.33 
Total 1.38 2.02 
9.70 2.26 
9.04 2.15 
Total 9.36 2.22 
3.35 1]0 
4.64 1.76 
Total 4.01 1.84 
4.81 2.79 
4.40 2.43 
Total 4.60 2.61 
0.81 1.37 
2.82 2.10 
Total 1.84 2.04 
7;58 2.35 
6.84 2.31 
Total 7.20 2.34 
enhancement (M=4.45, SD=1.48) ad versions. 
The olestra intention scores for the control and 
enhancement product disclosure statements 
did not differ significantly. All interaction 
effects involving ad version were nonsignficant 
(p>O.05). These findings indicate that the risk 
disclosure reduced behavioral intention to use 
olestra, but did not significantly influence 
intent to use the other weight loss products. 
Univariate analyses also found significant dif-
ferences among the behavioral intention [F 
(2,164) = 92.9, p<O.0001] and perceived risk [F 
(2,164) = 103.96, p<O.0001] scores for different 
product types. Bonferroni adjusted pairwise 
comparisons indicated that both high and low 
body dysphoric groups rated olestra iArith sig-
nificantly higher intentions to use and lower in 
perceived risk than sibutramine and PP A. Sibu-
tramine, a prescription medication, was rated 
with higher behavioral intention to use and 
lower in perceived risk than was PP A, an over-
the-counter medication. 
Objective two: Discriminators of high 
intention, and high and low body 
dysphoria 
A third hypothesis was that women with the 
highest levels of intention to use the weight 
loss products would have higher scores on 
measures of restrictive eating, concern for and 
perception of physical appearance, social and 
media pressure for thinness, and depression 
when compared to women with lower intention 
to use the three weight loss products. To test 
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this hypothesis, discriminant function analysis 
was conducted. This analysis tested whether 
eight variables (PRFQ: concern for physical 
appearance, media pressure for thinness, per-
ception of physical appearance, social pressure 
for thinness, BDI-II, TFEQ-restraint, disinhibi-
tion, and perceived hunger) differentiated 
women who obtained high scores on the 
behavioral intention scale for the three weight 
loss products, Women were defined as having 
high behavioral intention to use the products if 
they obtained a behavioral intention score 1.5 
SD or more above the mean for 2 out of the 3 
weight loss products, PPA and sibutramine. 
(Given the non-significant results for past 
usage and intention results for olestra, it was 
not used in these analyses.) According to these 
criteria, 12 women were classified as having 
high behavioral intention scores. Of these 12 
women, 11 were in the high body dysphoria 
group. A comparison group was obtained by 
randomly selecting an additional 12 women 
from the sample. The overall Wilks' Lambda 
was significant, A=O.29, X2 (8)=19.67, p=O.012, 
indicating that the two groups differed on their 
psychological profiles. The top of Table 4 pre-
sents the standardized canonical discriminant 
function coefficients as well as group means 
and SD. The discriminant analysis found that 
91 % of the individuals in the sample were cor-
rectly classified. Further, with the exception of 
TFEQ-H, the means for the high intention 
group were greater than the means for the low 
intention group across variables (F-values 
:2:14.21; p<0.01). 
A fourth hypothesis was that the high body 
dysphoria group would have higher scores on 
measures of restrictive eating, concern for and 
perception of physical appearance, social and 
media pressure for thinness, and depression 
when compared to the low body dysphoria 
group. To test this hypothesis, discriminant 
function analysis was conducted to determine if 
the same eight variables differentiated women 
previously classified as high (n=45) and low in 
body dysphoria (n=43). The overall Wilks' 
Lambda was significant, A=0.20, X2 (8) = 123.83, 
p <0 .01, indicating that the tVI'O groups differed 
on their psychological profiles. The bottom of 
Table 4 presents the standardized canonical 
discriminant function coefficients, group 
means, and SD. The discriminant analysis 
found that 100% of the individuals in the sam-
ple were correctly classified, and with the 
exception of TFEQ-H, the means for the high 
dysphoric group were greater than the means 
for the low dysphoric group across variables 
(F-values :2:29.46; p<O.01). 
The results suggested that women who had 
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strong intentions to use these weight loss prod-
ucts exhibited higher restraint, higher 
perceived social pressure thinness, lower 
perceived physical attractiveness, higher con-
cern for physical appearance, higher perceived 
media pressure for thinness, higher susceptibil-
ity for overeating, and higher levels of depres-
sion. Thus, the participants who expressed 
strong intentions to use these weight loss prod-
Hypothesis 3: Standardized ,..""I+ir'''''''. 
the discriminant 
predictor variables with 
STandardized 
Variable 
TFEQ-R 0.44 
PRFQ-Sf'T 0.42 
PRFQ-PPA -0.42 
PRFQ-CPA 0.40 
PRfQ~MPT 0.37 
TFEQ-D 0.36 
SDHI 0.35 
TFEQ-H -0.07 
Mea!l 
scorers 
13.]0(4.18) 
25.36 (2.91) 
14.64 (5.14) 
29.54 (4.46) 
24.09 (4.23) 
10.36(4.18) 
19.82 (8.44) 
7.09 (3.96) 
Mean (51)) 
Controls 
7.27{4.73)' 
19.27(6.20)* 
21.18(5.34)' 
22.18{7.52J* 
17.91(6.64)" 
6.45(4.46)· 
1O.27{9.80)* 
7.82(3.54) 
Hypothesis 4: Standardized coefficients and predictor variables with 
the discriminant function 
Standardized Mean {SO) Mean (SO) 
dysphoria !.ow dysphoria 
with 
fundion 
Variable 
TFEQ-R 0.51 11.86 (4.42) 4.05 (3.21)* 
PRFQ-SPT 0.25 24.31 (2.83) 17.08(5.10)' 
PRfQ-PPA -0.36 14.69 (4.60) 21.03(5.12)' 
PRFQ-CPA 0.04 27.29 (5.35) 20.43 (6.0B)· 
PRfQ-MPT 0.42 23.12 (3.05) 14.43 (4.25)' 
TfEQ-D 0.27 10.02 (3.23) 4.30 (3.84)' 
SDH! 0.33 18.71(8.62) 5.10 (4.49)' 
TfEQ-H -0.03 9.00(3.54) 6.75 i8.52) 
Nole: TFEQ-R '" Three-Fodor Eating Questionnaire Restrain! Scale; PRFQ-SPT '" 
Psychosocial Risk factors Quesfionnaire Social Pressure for Thinness Scale; PRFQ· 
PPA '" Psychosocial Risk foelors Questionnaire Perception of Physical 
Attractiveness Scale; PRFQ-CPA = Psychosocial Risk Factors Questionnaire 
Concern for Physico! Appearance Scale; PRFQ-MPT = Psychosocial Risk fadors 
Questionnaire Media Pressure for Thinness Scale; TFEQ-D = Three-factor Eating 
Questionnaire Disinhibition Scale; SOH! = Seck Depression Inventory-Second 
Edition; TfEQ-H '" Three-Factor Eating Questionnaire Perceived Hunger Scale 
'Differences belween groups are significant at the 0.01 !evel. 
ucts displayed many of the characteristics of 
persons diagnosed with an eating disorder but 
did not report the severity of symptoms that 
are commonly associated with eating disor-
ders. Similarly, high body dysphoric women 
scored higher than low body dysphoric women 
on the same seven body image variables. 
DISCUSSION 
Before discussing the findings of the study, it 
is important to recognize some of the limita-
tions of the study. The participants were young 
American women and the results should not be 
generalized to other cultures since many ethnic 
groups were not represented and the sample 
size was too small to allow for analyses of dif-
ferent ethnic groups. Also, the findings are 
based purely upon self-report of the partici-
pants. Therefore, we cannot conclude that 
these participants did in fact use the weight 
loss products simply because they reported an 
intention to do so. The results should be inter-
preted in the context of these considerations. 
This study tested how normal weight women 
with body dysphoria responded to information 
in weight loss ads. In addition, this study exam-
ined select body image variables that con-
tribute to an "at risk" group's intention to 
abuse weight loss products, and that discrimi-
nate between high and low body dysphoric 
groups. The hypothesis that normal weight 
women with high body dysphoria would have 
higher past usage and intention to use weight 
reduction products than would women with 
low levels of body dysphoria was largely sup-
ported. Specifically, high body dysphoric 
women reported higher intention to use the 
products in the future as well as actual higher 
prior use of two of the three weight loss prod-
ucts. However, women with high and low body 
dysphoria did not differ in their perceived risks 
for using the products, and in general, partici-
pants rated the weight loss products as having 
some health risks. (The overall means for risk, 
on a 0 to 12 scale, were 9.36 for PP A; 7.2 for 
sibutramine; and 4.6 for olestra.) This pattern 
of findings suggests that normal weight 
women "vith high levels of body dysphoria did 
not believe that these weight loss products 
were harmless. They recognized potential 
health risks associated with using such prod-
ucts, but nonetheless, expressed stronger 
intention to use these weight loss products. 
In the context of research on cognitive biases 
associated with body dysphoria, these findings 
suggest that information processing with these 
ads was not completely unbiased. It is likely 
weight loss products and normal weight women 
that high body dysphoric women had pre-
existing (and more favorable) attitudes about 
weight-loss products. Research on cognitive 
biases has postulated that strongly held beliefs 
Cschemas) influence the processing of food and 
diet related information, resulting in unhealthy 
behavior to control body weight and shape (7). 
Our findings are consistent with this view. 
The hypothesis that risk and intention would 
be affected by type of disclosure was not sup-
ported for two of three products. (Only olestra 
showed an effect). This finding is not consistent 
with the findings of previous studies (11, 24). One 
possible explanation might be that the ratings for 
intent to use PPA and sibutramine were general-
ly low across all participants (i.e., 1.38 for PPA 
and 1.84 for sibutramine on a scale of 0 to 8). 
Thus, a "floor" effect may have been operating 
making it difficult to detect the impact of deter-
rent disclosures. In comparison, the olestra rat-
ings were much higher than the PPA or sibu-
tramine ratings, which may have allowed the 
finding of a suppressive effect for the deterrent 
risk disclosure. These results are consistent, 
however, with research demonstrating that shni-
lar disclosures can have different effects across 
product categories that are viewed differently in 
terms of initial attitudes and risk (cf. 9 vs 23). 
There was no effect of ad disclosure on per-
ceived risk for any of the products. Even when 
risk factor information was added to the ads, 
participants did not rate the product as having 
more potential health risks, suggesting that 
women may have prior beliefs about the relative 
risks of certain products that are unchanged by 
information presented in the ads. This finding 
may have implications for future advertisement 
regulations, demonstrating the relative ineffec-
tiveness of warning labels and health risk disclo-
sures for certain types of products. Women with 
high body dysphoria indicated a general under-
standing of the risks involved with using the 
weight loss products regardless of wpich type of 
ad disclosure they received; however, knowledge 
of such health risks does not appear to be a 
deterrent for future use of such products. 
Perhaps reading about possible side effects is not 
an effective deterrent because it is not personally 
salient to the person. Future research should 
focus on developing effective methods for deter-
ring the inappropriate use of products that are 
potentially harmful. 
Though hypotheses were not formally 
advanced with regard to product type, partici-
pants in both groups exhibited a similar pattern 
of responding. Olestra was the most highly 
rated product (in terms of lowest risk and high-
est intention) followed by sibutramine and PP A. 
It is not surprising that olestra was the most 
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higbJy rated given that potato chips containing 
olestra are an easily accessible product even 
though the olestra L,l1gredient has been criticized 
by the Center for Science in the Public Interest 
for absorption and nutrient deprivation prob-
lems (25). However, the fact that ratings for 
sibutramine, a prescription medication, were 
more favorable than the ratings for PP A, an 
over-the-counter medication, was unexpected. A 
possible explanation for this is that people may 
be more trusting of medications that must be 
prescribed by a physician, thus affecting risk 
and intention. Thus, it is possible that prescrip-
tion medications may be at higher risk for abuse 
compared to OTC medications. A Significant 
number of participants reported prior use of the 
weight loss products despite their normal 
weight status. It was especially alarming that 
eleven women (20% of the high body dysphoria 
group) reported prior use of a prescription obe-
sity medication even though they were of nor-
mal weight. These products are explicitly not 
recommended for people who are not clinically 
obese because of the risk of side effects associat-
ed "vith use of the medications. Additionally, a 
large proportion of the women in the high body 
dysphoria group (47%) reported prior use of 
PP A or other OTC appetite suppressants. It is 
possible that the women who reported prior use 
of a prescription obesity medication or OTC 
appetite suppressant were obese while using the 
product, and lost enough weight to fall within a 
normal weight range and be eligible for partici-
pation in this study. However, given the serious 
side effect profile of these medications, future 
studies should address the question of the 
attainability of these medications and what mea-
sures could be taken to monitor improper use of 
such medications. 
The results of the discriminant analyses show 
that a subset of normal weight women rated 
their intentions to use weight loss products sig-
nificantly higher than the rest of the sample. 
Women at risk for inappropriate use of these 
products tended to actively restrain their eating, 
feel high pressure for thinness, and have higher 
levels of depression. Further, these same vari-
ables discriminated high and low body dysphoric 
groups. These results suggest that it is important 
for healthcare professionals and regulatory 
agencies to effectively identify women who are 
normal weight that are motivated to use poten-
tially harmful weight loss products. Thus, mental 
health professionals as well as physicians may be 
able to identify those women who are willing to 
use extreme measures to attain weight loss by 
using simple self-report measures such as those 
utilized in the present study. 
In summary, the results of this study suggest 
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that there is cause for concern regarding 
potential misuse of weight loss products. 
Advertisements featuring the products used in 
this study as well as countless others are grow-
ing in number. Women who do not need to 
lose weight but have significant body image 
concerns appear to be willing to use potentially 
harmful weight loss products despite the 
knowledge that such products may pose signif-
icant health risks. Techniques utilized by adver-
tising regulatory agencies such as warning 
labels do not appear to have a strong deterrent 
effect with normal weight women who are 
enrolled in college. Future research in this area 
should focus on developing ways to prevent the 
misuse of weight loss products through adver-
tising, medical and mental health screenings, 
and improved product labels. For example, 
more creative policy measures may be needed, 
such as the use of prominent "black box" warn-
ings employed for "fen-ph en" (26), and other 
visual cues for conveying risk information. 
Such disclosures may help at-risk women make 
more informed decisions. However, given that 
our results show that women high in body dys-
phoria understand the risks, but largely choose 
to ignore such risks, stronger control of such 
products may be needed. For example, it has 
been suggested that many doctors and clinics 
have attracted " at-risk" populations via ads for 
products that claim safe vveight loss. Our 
results pertaining to sibutramine and related 
prescription weight loss products are consis-
tent with this suggestion. It may be that federal 
agencies, such as the FDA, FTC, and CDC, 
need to become more involved in the dissemi-
nation of risk information and in the regulation 
of the health care professionals' role in the pro-
motion of weight loss products. 
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